Search

Your search keyword '"Tripathi, N."' showing total 8 results
Start Over Author "Tripathi, N." Journal annals of oncology
8 results on '"Tripathi, N."'

1. 1399P Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Author

Tripathi, N., primary, Chigarira, B., additional, Sayegh, N., additional, Mathew Thomas, V., additional, Adidam Kumar, S., additional, Goel, D., additional, Tandar, C., additional, Mcfarland, T.R., additional, Nussenzveig, R., additional, Sirohi, D., additional, Swami, U., additional, Maughan, B.L., additional, and Agarwal, N., additional

Published
2022
Full Text
View/download PDF

2. 1413P Tumor transcriptomic profiling of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who do not achieve optimal PSA response to intensified androgen deprivation therapy (ADT-I)

Author

Mathew Thomas, V., primary, Chigarira, B., additional, Sayegh, N., additional, Hernandez, E.J., additional, Tripathi, N., additional, Adidam Kumar, S., additional, Goel, D., additional, Tandar, C., additional, Mcfarland, T.R., additional, Yandell, M., additional, Nussenzveig, R., additional, Sirohi, D., additional, Swami, U., additional, Maughan, B.L., additional, and Agarwal, N., additional

Published
2022
Full Text
View/download PDF

3. 1373P SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)

Author

Swami, U., primary, Graf, R.P., additional, Nussenzveig, R., additional, Fisher, V., additional, Tukachinsky, H., additional, Li, G., additional, Sayegh, N., additional, Tripathi, N., additional, Mathew Thomas, V., additional, Oxnard, G.R., additional, Antonarakis, E.S., additional, and Agarwal, N., additional

Published
2022
Full Text
View/download PDF

4. 1899P Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)

Author

Gebrael, G., Jo, Y. Jung, Thomas, V. Mathew, Li, H., Fortuna, G. Galarza, Sahu, K., Sayegh, N., Tripathi, N., Chigarira, B., Srivastava, A., Chehade, C. Hage, Nordblad, B., Dal, E., Brundage, J., Maughan, B.L., Agarwal, N., and Swami, U.

Published
2023
Full Text
View/download PDF

5. 1898P Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)

Author

Swami, U., Jo, Y. Jung, Thomas, V. Mathew, Gebrael, G., Li, H., Sayegh, N., Tripathi, N., Srivastava, A., Nordblad, B., Dal, E., Brundage, J., Campbell, P., Fortuna, G. Galarza, Chehade, C. Hage, Maughan, B.L., and Agarwal, N.

Published
2023
Full Text
View/download PDF

6. 2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

Author

Sayegh, N., Jung Jo, Y., Gebrael, G., Tripathi, N., Chigarira, B., Srivastava, A., Nordblad, B., Dal, E., Hage Chehade, C., Maughan, B.L., Gupta, S., Agarwal, N., and Swami, U.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results